Ozmosi | Trevogrumab Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Trevogrumab

Alternative Names: trevogrumab, regn1033, sar391786
Clinical Status: Active
Latest Update: 2025-09-17
Latest Update Note: News Article

Product Description

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trevogrumab

Countries in Clinic: Puerto Rico, United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Regeneron presented P2 Obesity results on 2025-06-02 for Trevogrumab
  • Clinical Outcomes Reported - Regeneron announced they will present P2 Obesity results in 2H25 for Trevogrumab

Highest Development Phases

Phase 2: Obesity

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06299098

 COURAGE

P2

Active, not recruiting

Obesity

2026-05-13

50%

2025-07-18

Primary Endpoints

Recent News Events

Date

Type

Title

09/17/2025

News Article

 Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

06/02/2025

News Article

 Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

06/02/2025

News Article

 Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

01/13/2025

News Article

 Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions